Colorectal cancer DNA methylation patterns from patients in Manaus, Brazil

Abstract

BackgroundDNA methylation is commonly linked with the silencing of the gene expression for many tumor suppressor genes. As such, determining DNA methylation patterns should aid, in times to come, in the diagnosis and personal treatment for various types of cancers. Here, we analyzed the methylation pattern from five colorectal cancer patients from the Amazon state in Brazil for four tumor suppressor genes, viz.: DAPK, CDH1, CDKN2A, and TIMP2 by employing a polymerase chain reaction (PCR) specific to methylation. Efforts in the study of colorectal cancer are fundamental as it is the third most of highest incidence in the world.ResultsTumor biopsies were methylated in 1/5 (20 %), 2/5 (40 %), 4/5 (80 %), and 4/5 (80 %) for CDH1, CDKN2A, DAPK, and TIMP2 genes, respectively. The margin biopsies were methylated in 3/7 (43 %), 2/7 (28 %), 7/7 (100 %), and 6/7 (86 %) for CDH1, CDKN2A, DAPK, and TIMP2, respectively.ConclusionsOur findings showed DAPK and TIMP2 to be methylated in most samples from both tumor tissues and adjacent non-neoplastic margins; thus presenting distinct methylation patterns. This emphasizes the importance of better understanding of the relation of these patterns with cancer in the context of different populations.

The association, clinicopathological significance, and diagnostic value of <em>CDH1</em> promoter methylation in head and neck squamous cell carcinoma: a meta-analysis of 23 studies

“…Specifically, CDH1 , which encodes the cell adhesion protein E-cadherin, is an important TSG 55. Studies have shown that loss of CDH1 expression by promoter hypermethylation is involved in several types of cancer, including colorectal,56 lung,57 breast,23 and gastric cancers 58. This meta-analysis was done to resolve some of the inconsistent reports of the association between CDH1 promoter methylation and HNSCC 15,16…”

Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells

“…Nonetheless, an understanding of the underlying molecular mechanisms that play a major role in DAPk1's transcriptional regulation constitutes a prerequisite to the development of novel therapeutics against cancer and inflammation-associated diseases [175]. Strikingly enough, a detailed analysis of the mRNA and protein expression profile of DAPk1 in various tumor cell lines, including bladder, breast and renal carcinomas, led to the discovery of loss of DAPk1 expression [176].…”

Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins

“…It is expected that an understanding of the underlying molecular mechanisms regulating members of the DAPk family or triggering their associated death responses is essential to the development of DAPk based therapies to combat cancer and associated diseases [ 34 ]. As described earlier, DAPk1 and DAPk2 can be activated by several mechanisms, including binding of Ca 2+ -activated CaM, which allows the release of the catalytic domain from inhibition by the CaM autoregulatory domain, phosphorylation of ERK, and dephosphorylation of Ser308 [ 27 ].…”